FDA Drug Info Rounds pharmacists discuss FDA's ongoing safety review of adverse event reports in children who may have been unintentionally exposed to the drug through skin contact with women using Evamist.

FDA Drug Info Rounds pharmacists discuss new safety information about a possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, strengths and limitations of the studies, and recommendations for pharmacists.

Long-Acting Beta-Agonists (LABAs), a class of medications used for the treatment of asthma and chronic obstructive pulmonary disease (COPD), now have new recommendations in their drug label intended to promote their safe use in the treatment of asthma.

FDA Drug Info Rounds pharmacists discuss the differences between approved and unapproved colchicine products, concerns regarding unapproved single-ingredient oral colchicine, and how patients can offset the increased cost of Colcrys.